Réaction du greffon contre l’hôte après transplantation de cellules souches hématopoïétiques allogéniques

Mohamad Mohty
Chef(s) d'équipe(s) : Mohamad Mohty
Contact administratif : Olguine Trismercin

Faculté de médecine Pierre et Marie Curie – Site Saint-Antoine – 10ème étage
27, rue Chaligny – 75571 PARIS cedex 12

Professeurs, Maîtres de conférence, Chercheurs, Cliniciens
Post-doctorants, Chercheurs contractuels, Éméritat, Bénévolat
Ingénieurs, Techniciens
Doctorants, Master

Our team is focused on graft-versus host reactions after allogeneic stem cell transplantation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) has proven to be an effective therapy for a variety of life-threatening malignancies. However, allo-SCT is limited by the immunologic recognition and destruction of host tissues, termed graft-versus-host disease (GVHD). We develop translational studies aiming to decipher the different steps of the regulatory loops linking innate and adaptive immunity in GVHD target tissues. For this purpose, we characterize the status and function of dendritic cell subsets in GVHD as well as the different T helper subsets (Th1, Th17, Th22, Tfh and Treg) infiltrating the target tissues of GVHD (mainly skin and gut) or in the periphery before and after GVHD onset, and the nature and contribution of rare immune cells such as iNKT cells contained within the allogeneic graft to GVHD initiation or regulation. These approaches are dedicated  towards identification of GVHD biomarkers for predicting GVHD response to therapy, measurement of GVHD activity and distinguishing irreversible damage from continued GVHD activity, predicting the risk of developing long term deleterious GVHD, providing positive diagnosis of GVHD in clinically conflicting situations, and assessing prognosis of GVHD to guide therapeutic decisions.

Selected Publications :

  1. Brissot E,Bossard C,Malard F,Braudeau C,Chevallier P,Guillaume T,Delaunay J,Josien R,Gregoire M,Gaugler B,Mohty M. 2014. Involvement of the CX3CL1 (fractalkine)/CX3CR1 pathway in the pathogenesis of acute graft-versus-host disease. J Leukoc Biol. 2015 Feb;97(2):227-35.
  2. Lamarthée B, Malard F, Gamonet C, Bossard C, Couturier M, Renauld JC, Mohty M, Saas P, Gaugler B. 2015. Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10. Mucosal Immunol. Jul 8. doi: 10.1038/mi.2015.61.
  3. Peric Z, Cahu X, Malard F, Brissot E, Chevallier P, Guillaume T ,Gregoire M, Gaugler B, Mohty M. 2015. Peripheral Blood Plasmacytoid Dendritic Cells at Day 100 Can Predict Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug;21(8):1431-6.
  4. BrissotE,Clavert A,Blin N,Roland V,Guillaume T,Dubruille V,Mahe B,Gastinne T,Le Gouill S,Gaugler B,Moreau P,Mohty M. 2015. Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma. Leukemia 2015 10 2098-100
  5. Bossard, C., F. Malard, J. Arbez, P. Chevallier, T. Guillaume, J. Delaunay, J.F. Mosnier, P. Tiberghien, P. Saas, M. Mohty, and B. Gaugler. 2012. Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. Leukemia 26:1471-1474.


Centre de Recherche
UMR_S 938

Hôpital St-Antoine


Tél : +(33) 1 49 28 46 89